| Outcome Measures: |
Primary: AUCI287,0-840h,SD: Area under the serum insulin 287 concentration-time curve after a single dose, Measured in pmol\*h/L, From 0 to 840 hours after trial product administration (visit 2 (study day 1)) | Secondary: Cmax,I287,SD: Maximum observed serum insulin 287 concentration after a single dose, Measured in pmol/L, From 0 to tz hours after trial product administration (visit 2 (study day 1)), where tz is the time of the last quantifiable concentration|tmax,I287,SD: Time to maximum observed serum insulin 287 concentration after a single dose, Measured in hours, From 0 to tz hours after trial product administration (visit 2 (study day 1)).|Number of adverse events, Number of events, From trial product administration (visit 2 (study day 1)) until visit 13 (study day 43)|Change in anti-insulin 287 antibody level, Measured in % B/T (percentage of bound tracer measured after precipitation to total tracer), From visit 2 (study day 1, pre-dose) to visit 13 (study day 43)|Change in anti-insulin 287 antibody titres, Number of dilutions, From visit 2 (study day 1, pre-dose) to visit 13 (study day 43)|Positive cross-reactive anti-human insulin antibodies, Number of patients with/without positive cross-reactive anti-human insulin antibodies, At visit 13 (study day 43)
|
